公开(公告)号：US07521004B2

公开(公告)日：2009-04-21

申请号：US10572098

申请日：2004-09-14

申请人： Junji Momoda ,  Yuichiro Kawabata ,  Nobuyuki Tanaka ,  Arihiro Iwata

发明人： Junji Momoda ,  Yuichiro Kawabata ,  Nobuyuki Tanaka ,  Arihiro Iwata

IPC分类号： F21V9/00 ,  G02B5/02 ,  G02C7/10 ,  G02F1/361 ,  G03B11/00

CPC分类号： C07D311/94 ,  C07D311/96 ,  C07D405/04 ,  C07D409/04 ,  C09K9/02 ,  C09K2211/1011 ,  C09K2211/1077

摘要： A chromene compound of this invention, as shown in the following formula: characterized by having an indeno(2,1-f)naphtho(1,2-b)pyran structure as a basic structure, and having a substituent which is a substituted or unsubstituted aryl group such as methoxyphenyl group, or a substituted or unsubsterituted heteroaryl group such as thienyl group bonding to a carbon atom at the seventh position of the indeno(2,1-f)naphtho(1,2-b)pyran structure. The photochromic compound exhibits a color tone of a neutral tint when it develops a color, features a high color-developing sensitivity and a high fading rate, and has a good photochromic resistance.

摘要翻译： 本发明的色烯化合物，如下式所示：其特征在于具有茚并（2,1-f）萘并（1,2-b）吡喃结构作为碱性结构，并具有取代基或取代或取代的取代基 未取代的芳基如甲氧基苯基，或取代或未取代的杂芳基如噻吩基与茚并（2,1-f）萘并（1,2-b）吡喃结构的第七位上的碳原子键合。 光致变色化合物在显色时具有中性色调的色调，具有高显色灵敏度和高褪色速度，并具有良好的光致变色性。

公开(公告)号：US20070215844A1

公开(公告)日：2007-09-20

申请号：US10572098

申请日：2004-09-14

申请人： Junji Momoda ,  Yuichiro Kawabata ,  Nobuyuki Tanaka ,  Arihiro Iwata

发明人： Junji Momoda ,  Yuichiro Kawabata ,  Nobuyuki Tanaka ,  Arihiro Iwata

IPC分类号： F21V9/06 ,  C07D311/78

CPC分类号： C07D311/94 ,  C07D311/96 ,  C07D405/04 ,  C07D409/04 ,  C09K9/02 ,  C09K2211/1011 ,  C09K2211/1077

摘要： A chromene compound of this invention, as shown in the following formula: characterized by having an indeno(2,1-f)naphtho(1,2-b)pyran structure as a basic structure, and having a substituent which is a substituted or unsubstituted aryl group such as methoxyphenyl group, or a substituted or unsubstituted heteroaryl group such as thienyl group bonding to a carbon atom at the seventh position of the indeno(2,1-f)naphtho(1,2-b)pyran structure. The photochromic compound exhibits a color tone of a neutral tint when it develops a color, features a high color-developing sensitivity and a high fading rate, and has a good photochromic resistance.

摘要翻译： 本发明的色烯化合物，如下式所示：其特征在于具有茚并（2,1-f）萘并（1,2-b）吡喃结构作为碱性结构，并具有取代基或取代或取代的取代基 未取代的芳基如甲氧基苯基或取代或未取代的杂环基，例如与茚并（2,1-f）萘并（1,2-b）吡喃结构的第七位上的碳原子键合的噻吩基。 光致变色化合物在显色时具有中性色调的色调，具有高显色灵敏度和高褪色速度，并具有良好的光致变色性。

公开(公告)号：US08691926B2

公开(公告)日：2014-04-08

申请号：US11667317

申请日：2005-11-08

申请人： Nobuyuki Tanaka ,  Junji Momoda

发明人： Nobuyuki Tanaka ,  Junji Momoda

IPC分类号： C08F236/20 ,  C08F236/22 ,  C08F4/32

CPC分类号： C08F222/1006 ,  G02B1/041

摘要： A polymerization curable composition prepared by blending specific amounts of a photochromic compound and a specific light stabilizer such as bis(1,2,2,6,6-pentamethyl-4-piperidyl)sebacate with monomer components including a specific bifunctional monomer having a structure that two phenylene groups are bonded together by a specific group, such as 2,2-bis(4-methacryloyloxypolyethoxyphenyl)propane, a polyfunctional polymerizable monomer having a functionality of 3 or more such as trimethylolpropane trimethacrylate, and a monomer other than these in a specific ratio.The polymerization curable composition provides a cured product having excellent photochromic properties such as fast fading rate and sufficiently high drilling strength that allows for its use in rimless spectacles and has high long-term storage stability.

摘要翻译： 通过将特定量的光致变色化合物和特定光稳定剂如双（1,2,2,6,6-五甲基-4-哌啶基）癸二酸酯与单体组分共混而制备的聚合可固化组合物，所述单体组分包括具有结构的特定双官能单体 两个亚苯基通过特殊基团结合在一起，例如2,2-双（4-甲基丙烯酰氧基聚乙氧基苯基）丙烷，官能度为3以上的多官能团聚合性单体，例如三羟甲基丙烷三甲基丙烯酸酯，以及除 具体比例。 聚合可固化组合物提供了具有优异的光致变色特性的固化产物，例如快速褪色速率和足够高的钻孔强度，其允许其在无框眼镜中使用并且具有高的长期储存稳定性。

公开(公告)号：US20080058444A1

公开(公告)日：2008-03-06

申请号：US11667317

申请日：2005-11-08

申请人： Nobuyuki Tanaka ,  Junji Momoda

发明人： Nobuyuki Tanaka ,  Junji Momoda

IPC分类号： C08F20/04

CPC分类号： C08F222/1006 ,  G02B1/041

摘要： A polymerization curable composition prepared by blending specific amounts of a photochromic compound and a specific light stabilizer such as bis(1,2,2,6,6-pentamethyl-4-piperidyl)sebacate with monomer components including a specific bifunctional monomer having a structure that two phenylene groups are bonded together by a specific group, such as 2,2-bis(4-methacryloyloxypolyethoxyphenyl)propane, a polyfunctional polymerizable monomer having a functionality of 3 or more such as trimethylolpropane trimethacrylate, and a monomer other than these in a specific ratio. The polymerization curable composition provides a cured product having excellent photochromic properties such as fast fading rate and sufficiently high drilling strength that allows for its use in rimless spectacles and has high long-term storage stability.

摘要翻译： 通过将特定量的光致变色化合物和特定光稳定剂如双（1,2,2,6,6-五甲基-4-哌啶基）癸二酸酯与单体组分共混而制备的聚合可固化组合物，所述单体组分包括具有结构的特定双官能单体 两个亚苯基通过特殊基团结合在一起，例如2,2-双（4-甲基丙烯酰氧基聚乙氧基苯基）丙烷，官能度为3以上的多官能团聚合性单体，例如三羟甲基丙烷三甲基丙烯酸酯，以及除 具体比例。 聚合可固化组合物提供了具有优异的光致变色特性的固化产物，例如快速褪色速率和足够高的钻孔强度，其允许其在无框眼镜中使用并且具有高的长期储存稳定性。

公开(公告)号：US08957219B2

公开(公告)日：2015-02-17

申请号：US13124788

申请日：2009-10-15

申请人： Koji Masuda ,  Shiro Kida ,  Kyohei Hayashi ,  Manabu Katou ,  Naoki Yoshikawa ,  Akira Kugimiya ,  Mado Nakajima ,  Nobuyuki Tanaka

发明人： Koji Masuda ,  Shiro Kida ,  Kyohei Hayashi ,  Manabu Katou ,  Naoki Yoshikawa ,  Akira Kugimiya ,  Mado Nakajima ,  Nobuyuki Tanaka

IPC分类号： A61K31/426 ,  A61K31/428 ,  C07D513/02 ,  C07D513/04 ,  C07D235/16 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/429 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D263/56 ,  C07D417/04 ,  C07D417/12

CPC分类号： C07D235/16 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/429 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D263/56 ,  C07D263/57 ,  C07D277/30 ,  C07D277/64 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D513/04

摘要： Disclosed is a compound which is useful as an endothelial lipase inhibitor.A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by the formula: —C(R1R2)—C(═O)—NR3R4 and a group represented by the formula: —R5, a broken line represents the presence or the absence of a bond, Z is —NR6—, ═N—, —O—, or —S—, R6 is halogen, substituted or unsubstituted alkyl or the like, R1 and R2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is hydrogen, substituted or unsubstituted alkyl or the like, R3 and R4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like.

摘要翻译： 公开了可用作内皮脂肪酶抑制剂的化合物。 一种具有对内皮脂肪酶具有抑制活性的药物组合物，其包含由下式表示的化合物：其药学上可接受的盐或其溶剂合物，其中环A是含氮杂环，环A可以被除代表的基团以外的取代基取代 通式为-C（R 1 R 2）-C（= O）-NR 3 R 4和由式-R 5表示的基团，虚线表示键的存在或不存在，Z为-NR 6 - ，= ，-O-或-S-，R 6为卤素，取代或未取代的烷基等，R 1和R 2各自独立地为氢，卤素，羟基，氰基，硝基，羧基或取代或未取代的烷基，R 3为氢或取代 或未取代的烷基，R 4为氢，取代或未取代的烷基等，R 3和R 4与它们所连接的相邻氮原子一起形成取代或未取代的环，R 5为氢，卤素，羟基，氰基，硝基 ，ca 取代或未取代的烷基，取代或未取代的链烯基，取代或未取代的炔基等。

公开(公告)号：US20130317715A1

公开(公告)日：2013-11-28

申请号：US13983105

申请日：2011-02-04

申请人： Keiji Kaita ,  Nobuyuki Tanaka ,  Masaya Amano ,  Koji Hokoi ,  Masashi Yoshimi ,  Takeshi Hoshiba ,  Takahiko Hirasawa

发明人： Keiji Kaita ,  Nobuyuki Tanaka ,  Masaya Amano ,  Koji Hokoi ,  Masashi Yoshimi ,  Takeshi Hoshiba ,  Takahiko Hirasawa

IPC分类号： F16H61/12

CPC分类号： F16H61/12 ,  F16H59/105 ,  F16H2061/1284 ,  F16H2061/168

摘要： An ECU determines whether or not there is an abnormality (shift pattern abnormality) in a combination of shift signals provided from a shift position sensor. After occurrence of the shift pattern abnormality is determined, the ECU determines whether or not a first condition that a shift pattern changes into a normal pattern of a drive range is satisfied, and whether or not a second condition that a vehicle is running (a driver has an intention to cause the vehicle to run) is satisfied. When occurrence of the shift pattern abnormality is determined, the ECU stops generation of driving force of the vehicle and prohibits switching to the drive range. When the above-mentioned first condition and second condition are satisfied after occurrence of the shift pattern abnormality is determined, the ECU switches the shift range to the drive range indicated by the shift pattern and recovers the driving force.

摘要翻译： ECU根据从换档位置传感器提供的换档信号的组合，判定是否存在异常（换档模式异常）。 在确定了发生换档模式异常之后，ECU判定是否满足了换档方式变为驱动范围的正常模式的第一状态，以及车辆是否正在行驶的第二状态（驾驶员 意图使车辆行驶）满足。 当发生换档模式异常时，ECU停止生成车辆的驱动力并禁止切换到驱动范围。 当确定发生换档模式异常之后满足上述第一条件和第二条件时，ECU将换档范围切换到由换档模式指示的驱动范围并恢复驱动力。

公开(公告)号：US08402575B2

公开(公告)日：2013-03-26

申请号：US13549805

申请日：2012-07-16

申请人： Nobuyuki Tanaka ,  Kenichi Tanaka ,  Kazuo Mishina

发明人： Nobuyuki Tanaka ,  Kenichi Tanaka ,  Kazuo Mishina

IPC分类号： A61G7/08

CPC分类号： A61G7/103

摘要： A between-bed-and-wheelchair move assist apparatus arranged to facilitate a caregiver to help a care receiver to move between a bed and a wheelchair, said between-bed-and-wheelchair move assist apparatus comprising a support member mounted in a side rail mount hole of the bed; and a slide board mounted on the support member so as to bridge between a surface of a mat on the bed and the seat surface of a wheelchair by sliding on the mat on the bed and stretching toward the wheelchair from a position on the bed.

摘要翻译： 一种床和轮椅移动辅助装置，其布置成便于护理者帮助护理接收器在床和轮椅之间移动，所述床与轮椅移动辅助装置包括安装在侧轨中的支撑构件 床的安装孔; 以及滑动板，其安装在所述支撑构件上，以便通过在所述床上的所述垫上滑动并且从所述床上的位置朝向所述轮椅拉伸而在所述床上的垫的表面和轮椅的座面之间桥接。

公开(公告)号：US08208953B2

公开(公告)日：2012-06-26

申请号：US12919749

申请日：2009-02-25

申请人： Nobuyuki Tanaka

发明人： Nobuyuki Tanaka

IPC分类号： H04B7/00

CPC分类号： H04W52/346 ,  H04L5/0007 ,  H04L5/0053 ,  H04L5/0082 ,  H04L5/0091 ,  H04L27/2602 ,  H04L27/2647 ,  H04W52/48 ,  H04W52/50 ,  H04W74/004 ,  H04W74/006 ,  H04W76/10 ,  H04W88/02

摘要： A mobile station (14) transmits a connection request signal (TCCH) to a base station (12) (S102), and detects whether or not a connection response signal (SCCH) is received from the base station (12) within a predetermined period of time. If the connection response signal (SCCH) is not received within the predetermined period of time, the mobile station (14) decreases the number of subcarriers used for transmitting a radio signal to the base station (12), increases transmission power per subcarrier by an amount of power corresponding to an amount of decrease in the number of subcarriers (S104), and retransmits the connection request signal (TCCH) (S106).

摘要翻译： 移动站（14）向基站（12）发送连接请求信号（TCCH）（S102），并且检测在预定周期内是否从基站（12）接收到连接响应信号（SCCH） 的时间。 如果在预定时间段内没有接收到连接响应信号（SCCH），则移动站（14）将用于向基站（12）发送无线电信号的子载波数量减少，从而将每个副载波的发送功率增加一个 对应于子载波数量减少量的功率量（S104），并重传连接请求信号（TCCH）（S106）。

公开(公告)号：US20110251386A1

公开(公告)日：2011-10-13

申请号：US13124788

申请日：2009-10-15

申请人： Koji Masuda ,  Shiro Kida ,  Kyohei Hayashi ,  Manabu Katou ,  Naoki Yoshikawa ,  Akira Kugimiya ,  Mado Nakajima ,  Nobuyuki Tanaka

发明人： Koji Masuda ,  Shiro Kida ,  Kyohei Hayashi ,  Manabu Katou ,  Naoki Yoshikawa ,  Akira Kugimiya ,  Mado Nakajima ,  Nobuyuki Tanaka

IPC分类号： C07D417/12 ,  C07D417/10 ,  C07D277/30 ,  C07D263/57 ,  C07D277/64 ,  C07D513/04

CPC分类号： C07D235/16 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/429 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D263/56 ,  C07D263/57 ,  C07D277/30 ,  C07D277/64 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D513/04

摘要： Disclosed is a compound which is useful as an endothelial lipase inhibitor.A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by the formula: —C(R1R2)—C(═O)—NR3R4 and a group represented by the formula: —R5, a broken line represents the presence or the absence of a bond, Z is —NR6—, ═N—, —O—, or —S—, R6 is halogen, substituted or unsubstituted alkyl or the like, R1 and R2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is hydrogen, substituted or unsubstituted alkyl or the like, R3 and R4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like.

摘要翻译： 公开了可用作内皮脂肪酶抑制剂的化合物。 一种具有对内皮脂肪酶具有抑制活性的药物组合物，其包含由下式表示的化合物：其药学上可接受的盐或其溶剂合物，其中环A是含氮杂环，环A可以被除代表的基团以外的取代基取代 通式为-C（R 1 R 2）-C（= O）-NR 3 R 4和由式-R 5表示的基团，虚线表示键的存在或不存在，Z为-NR 6 - ，= ，-O-或-S-，R 6为卤素，取代或未取代的烷基等，R 1和R 2各自独立地为氢，卤素，羟基，氰基，硝基，羧基或取代或未取代的烷基，R 3为氢或取代 或未取代的烷基，R 4为氢，取代或未取代的烷基等，R 3和R 4与它们所连接的相邻氮原子一起形成取代或未取代的环，R 5为氢，卤素，羟基，氰基，硝基 ，ca 取代或未取代的烷基，取代或未取代的链烯基，取代或未取代的炔基等。

公开(公告)号：US07923462B2

公开(公告)日：2011-04-12

申请号：US12810275

申请日：2008-12-22

申请人： Takehiro Ishikawa ,  Hitoshi Inoue ,  Satoko Kobayashi ,  Masako Yoshida ,  Hiroaki Shiohara ,  Yasunori Ueno ,  Nobuyuki Tanaka

发明人： Takehiro Ishikawa ,  Hitoshi Inoue ,  Satoko Kobayashi ,  Masako Yoshida ,  Hiroaki Shiohara ,  Yasunori Ueno ,  Nobuyuki Tanaka

IPC分类号： A61K31/4245 ,  A61K31/427 ,  C07D271/06 ,  C07D413/04 ,  C07D417/10 ,  A61P25/16

CPC分类号： C07D271/06 ,  C07D413/04 ,  C07D413/10 ,  C07D417/10

摘要： The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen, lower acyl, lower alkoxycarbonyl or the like; R3 is halo-lower alkyl, lower acyl, halo-lower alkylcarbonyl, cycloalkylcarbonyl, optionally substituted arylcarbonyl, lower alkoxycarbonyl or the like; R4 is lower alkyl, halo-lower alkyl, cycloalkyl, lower alkoxy-lower alkyl or the like, which exhibit potent COMT inhibitory activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

摘要翻译： 本发明提供由通式（I）表示的化合物或其药学上可接受的盐，其中R 1和R 2各自为氢，低级酰基，低级烷氧基羰基等; 低级酰基，卤代低级烷基羰基，环烷基羰基，任意取代的芳基羰基，低级烷氧基羰基等; R4是表现出强大的COMT抑制活性的低级烷基，卤代低级烷基，环烷基，低级烷氧基 - 低级烷基等。 本发明还提供含有所述化合物的药物组合物及其用途。